hm30181
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT01491204)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Multidrug resistance protein 3INHIBITOR
ABCB4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-oxo-4h-chromene-2-carboxylic acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl)-phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide
- hm30181
- hm30181
- hm30181
- hm-30181
- hm30181ak
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00954304 | Phase 1 | Jun 1, 2009 | Hanmi Pharmaceutical, Seoul National University |
| NCT00979563 | Phase 1 | Jul 1, 2008 | Hanmi Pharmaceutical, University of Ulsan |
| NCT00986843 | Phase 1 | Jun 1, 2008 | Hanmi Pharmaceutical, Seoul National University |
| NCT01491204 | Phase 1 | Aug 1, 2006 | Hanmi Pharmaceutical |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 4 | 4 | 1 | 2006 |
| Seoul National University | Academic/Hospital | 2 | 0 | 1 | 2008 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1